“‘Rarely is one afforded a glimpse into the dark heart of the contemporary “Heath Reform” project as unwittingly honest and searing as that provided by an exchange of opinions between Mark Thornton, in a Wall Street Journal op-ed regarding the FDA’s approval process for investigational cancer treatments, and a Dr. James Smith, replying in the Letters to the Editor page on May 13′” 

“Towers Watson, a leading human resources consulting firm, has conducted a survey of 661 human resource and benefit specialists across America. While benefit professionals are still digesting the new law, the survey shows that they are even more skeptical of Obamacare than the public is.”

“Is the Pill preventive, in the sense meant when preventive medicine got debated during ObamaCare?  Not at all.  Democrats specifically called out early diagnosis of diseases such as diabetes….That never included an explicit argument that lowering the birth rate would be an overall cost-saver, or that it was a legitimate government interest to suppress the birth rate. “

Though ObamaCare’s “Cadillac plan” tax was designed to affect only employers with extravagant health benefit plans, an analysis by the global professional services company Towers Watson, using data from its 2010 Health Care Cost Survey, reveals that more than 60% of large employers’ health-care plans could be subject to this tax when it goes into effect in 2018.

Michigan, a state that Barack Obama won by 16 points and which hasn’t gone to a Republican presidential candidate in 22 years, opposes ObamaCare by 8 points — with voters under age-30 being opposed to it by more than 2-to-1.

At a time of nearly 10 percent unemployment, 90 companies have already reported reduced earnings because of ObamaCare — with most of them reporting reduced earnings of more than $1 million.

Medical device manufacturers say they would have to lay off workers and curb the research and development of new medical tools as a result of ObamaCare’s 2.3 percent tax on medical devices — a tax which would cost these companies an estimated $20 billion over the next decade.